Literature DB >> 31653462

Urodynamic and imaging findings in infants with myelomeningocele may predict need for future augmentation cystoplasty.

Lauren E Corona1, Ted Lee2, Kathryn Marchetti2, Courtney S Streur2, Vesna Ivancic2, Kate H Kraft2, David A Bloom2, Julian Wan2, John M Park2.   

Abstract

INTRODUCTION: Urologic issues are persistent and important causes of morbidity and mortality in patients with myelomeningocele. Classically, patients with elevated bladder pressures despite adherence to clean intermittent catheterization (CIC) and pharmacotherapy undergo augmentation cystoplasty (AC). Currently, there is little understanding of which infants are more likely to require AC later.
OBJECTIVE: In this context, the authors studied whether unfavorable urodynamic or imaging findings in patients with myelomeningocele during infancy could predict future AC. The authors hypothesized that infants born with elevated bladder pressures, vesicoureteral reflux (VUR), and/or hydronephrosis would be more likely to undergo AC. STUDY
DESIGN: The authors retrospectively identified patients with myelomeningocele at their institution who were followed-up since infancy (<1 year of age), with a minimum of eight continuous years of follow-up. Standard care protocol included cystometrogram, voiding cystourethrogram (VCUG), and renal ultrasound during infancy. The primary outcome was AC for elevated bladder pressures despite attempts at more conservative management with medical therapy and CIC. Specifically, the authors evaluated for differences in augmentation rates based on gender, level of lesion, presence of detrusor leak point pressure (DLPP) or end-fill pressure (EFP) greater than 40 cm H2O, presence of hydronephrosis, VUR, initiation of CIC, and initiation of antimuscarinics in infancy. The authors excluded patients who underwent surgical intervention for urinary incontinence.
RESULTS: A total of 97 patients met the inclusion criteria. The median follow-up time was 13.8 years. Augmentation cystoplasty was performed for 17 patients (17.5%) at a median age of 114 months (9.5 years). Detrusor leak point pressure/EFP was greater than 40 cm H2O in 34.0% (33/97) of infant cystometrogram studies, while 30.9% (30/97) had VUR on infant VCUG and 20.6% (20/97) had hydronephrosis on infant renal ultrasound. Patients with DLPP/EFP greater than 40 cm H2O or VUR during infancy were more likely to undergo AC (P = 0.02 and P = 0.03, respectively). Binomial logistic regression revealed that DLPP/EFP greater than 40 cm H2O (odds ratio [OR]: 4.28, 95% confidence interval [CI]: 1.34-13.62) and VUR (OR: 3.73, 95% CI: 1.18-11.77) were independent risk factors for future AC. DISCUSSION: Infants with myelomeningocele and elevated bladder pressures and VUR should be closely monitored by urodynamic testing and imaging studies. Parents can be counseled regarding the potentially higher risk for future AC in these patients. Nonetheless, the majority of high-risk infants will safely avoid AC with conservative management.
Copyright © 2019 Journal of Pediatric Urology Company. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Augmentation cystoplasty; Detrusor leak point pressure; Myelomeningocele; Vesicoureteral reflux

Mesh:

Year:  2019        PMID: 31653462      PMCID: PMC7086486          DOI: 10.1016/j.jpurol.2019.09.015

Source DB:  PubMed          Journal:  J Pediatr Urol        ISSN: 1477-5131            Impact factor:   1.830


  13 in total

1.  Improved survival among children with spina bifida in the United States.

Authors:  Mikyong Shin; James E Kucik; Csaba Siffel; Chengxing Lu; Gary M Shaw; Mark A Canfield; Adolfo Correa
Journal:  J Pediatr       Date:  2012-06-23       Impact factor: 4.406

Review 2.  Update on Urological Management of Spina Bifida from Prenatal Diagnosis to Adulthood.

Authors:  Devon C Snow-Lisy; Elizabeth B Yerkes; Earl Y Cheng
Journal:  J Urol       Date:  2015-04-01       Impact factor: 7.450

3.  Expectation of life and unexpected death in open spina bifida: a 40-year complete, non-selective, longitudinal cohort study.

Authors:  Pippa Oakeshott; Gillian M Hunt; Alison Poulton; Fiona Reid
Journal:  Dev Med Child Neurol       Date:  2009-12-09       Impact factor: 5.449

4.  Improved bladder function after prophylactic treatment of the high risk neurogenic bladder in newborns with myelomentingocele.

Authors:  M Kaefer; A Pabby; M Kelly; M Darbey; S B Bauer
Journal:  J Urol       Date:  1999-09       Impact factor: 7.450

Review 5.  Conservative management in neurogenic bladder dysfunction.

Authors:  Ahmet R Aslan; Barry A Kogan
Journal:  Curr Opin Urol       Date:  2002-11       Impact factor: 2.309

6.  Issues of medical management in adults with spina bifida.

Authors:  G V McDonnell; J P McCann
Journal:  Childs Nerv Syst       Date:  2000-04       Impact factor: 1.475

7.  Neurogenic bladder dysfunction due to myelomeningocele: neonatal versus childhood treatment.

Authors:  H Y Wu; L S Baskin; B A Kogan
Journal:  J Urol       Date:  1997-06       Impact factor: 7.450

8.  External urethral sphincter dilation for the management of high risk myelomeningocele: 15-year experience.

Authors:  J M Park; E J McGuire; H P Koo; A C Schwartz; C K Garwood; D A Bloom
Journal:  J Urol       Date:  2001-06       Impact factor: 7.450

9.  Is 40 cm H2 O detrusor leak point pressure cut-off reliable for upper urinary tract protection in children with myelodysplasia?

Authors:  Tufan Tarcan; Cagri Akin Sekerci; Cem Akbal; Ilker Tinay; Yiloren Tanidir; Ahmet Sahan; Bahadir Sahin; Tuncay Top; Ferruh Simsek
Journal:  Neurourol Urodyn       Date:  2016-04-15       Impact factor: 2.696

10.  Design and Methodological Considerations of the Centers for Disease Control and Prevention Urologic and Renal Protocol for the Newborn and Young Child with Spina Bifida.

Authors:  Jonathan C Routh; Earl Y Cheng; J Christopher Austin; Michelle A Baum; Patricio C Gargollo; Richard W Grady; Adrienne R Herron; Steven S Kim; Shelly J King; Chester J Koh; Pangaja Paramsothy; Lisa Raman; Michael S Schechter; Kathryn A Smith; Stacy T Tanaka; Judy K Thibadeau; William O Walker; M Chad Wallis; John S Wiener; David B Joseph
Journal:  J Urol       Date:  2016-07-27       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.